Last reviewed · How we verify

NCT05361161

Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)

Status unknown Phase 2 Last updated 24 May 2022
What this trial tests

Phase 2 trial testing Transarterial Chemoembolization in Gastric Cancer in 60 participants. Status unknown.

Timeline
1 June 2022
Primary endpoint
1 December 2022
1 December 2025

Quick facts

Lead sponsorGang Wu
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 June 2022
Primary completion1 December 2022
Estimated completion1 December 2025

Drugs / interventions tested

Conditions studied

Sponsor

Gang Wu — full company profile →

Who can join

Adults 18 to 80, any sex, with Gastric Cancer or Embolization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, open-labelled study to evaluate the efficacy and safety of sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of Initial unresectable gastric cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transarterial Chemoembolization

Trials testing the same drug.

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

Other Gang Wu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05361161.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing